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Abstract
Background: Thrombolytic therapy is recommended for patients with acute ST-segment elevation myo - 
cardial infarction (STEMI) who cannot undergo primary percutaneous coronary intervention within 
the first 120 min. The aim of this study was to demonstrate the value of CHA2DS2-VASc and CHA2DS2-
-VASc-HS scores in predicting failed reperfusion in STEMI patients treated with thrombolytic therapy.
Methods: A total of 537 consecutive patients were enrolled in the study; 139 had failed thrombolysis 
while the remaining 398 fulfilled the criteria for successful thrombolysis. Thrombolysis failure was 
defined with the lack of symptom relief, < 50% ST resolution-related electrocardiography within  
90 min from initiation of the thrombolytic therapy, presence of hemodynamic or electrical instability 
or in-hospital mortality. CHA2DS2-VASc and CHA2DS2-VASc-HS scores, which incorporate hyperlipi-
demia, smoking, switches between female and male gender, were previously shown to be markers of the 
severity of coronary artery disease (CAD). 
Results: History of hypertension, diabetes mellitus, hyperlipidemia, heart failure, smoking, and CAD 
were significantly common in failed reperfusion patients (for all; p < 0.05). For prediction of failed rep-
erfusion, the cut-off value of CHA2DS2-VASc score was ≥ 2 with a sensitivity of 80.90% and a specificity 
of 41.01% (area under curve [AUC] 0.660; 95% confidence interval [CI] 0.618–0.700; p < 0.001) and 
the cut-off value of CHA2DS2-VASc-HS score was ≥ 3 with a sensitivity of 76.13% and a specificity of 
67.63% (AUC 0.764; 95% CI 0.725–0.799; p < 0.001). The CHA2DS2-VASc-HS score was found to be 
statistically and significantly better than CHA2DS2-VASc score to predict failed reperfusion (p < 0.001).
Conclusions: The findings suggest that the CHA2DS2-VASc and especially CHA2DS2-VASc-HS scores 
could be considered as predictors of risk of failed reperfusion in STEMI patients. (Cardiol J 2019; 26, 
2: 169–175)
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Introduction 
Acute reperfusion, performed either with 
thrombolytic therapy or primary percutaneous 
coronary intervention (PCI), is the mainstay of 
treatment for patients experiencing an acute 
ST-segment elevation myocardial infarction 
(STEMI). Although contemporary guidelines for 
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acute STEMI patients recommend primary PCI as 
the preferred reperfusion strategy, most patients 
do not present to a PCI-capable hospital [1]. Thus, 
thrombolysis remains the treatment of choice for 
STEMI patients when a PCI cannot be performed 
within the first 120 min or it is delayed due to 
patient transfer. A routine coronary angiography 
is recommended 2–24 h after thrombolytic ther-
apy, and a rescue PCI should be performed when 
thrombolytic therapy fails [1]. Reperfusion fails in 
almost one third of patients receiving thrombolytic 
therapy, and these patients require a rescue PCI 
[2, 3]. Estimating the risk of reperfusion failure 
in individual patients before initiation of throm-
bolytic therapy may be helpful to determine the 
optimal treatment strategy especially for patients 
admitted to non-PCI capable hospitals. Previous 
studies reported that parameters such as red cell 
distribution width, mean platelet volume, platelet 
distribution width and C-reactive protein (CRP) 
on admission may be helpful in predicting failed 
reperfusion [4–7]. However, according to available 
literature, there is currently no scoring system 
which can be used to predict failed reperfusion in 
STEMI patients to whom thrombolytic therapy is 
given. The CHA2DS2-VASc score is traditionally 
used for thromboembolic risk stratification in atrial 
fibrillation (AF) patients [8]. The components of the 
CHA2DS2-VASc score, namely hypertension (HT), 
diabetes mellitus (DM), old age, and heart failure, 
were also shown to be risk factors for poor clini-
cal outcomes in cardiovascular diseases. Recent 
studies demonstrated that CHA2DS2-VASC score 
can also predict poor clinical outcomes in stable 
coronary artery disease (CAD) and acute coronary 
syndrome, irrespective of the presence of AF 
[9, 10]. Cetin et al. [9] demonstrated that CHADS2, 
CHA2DS2-VASc and the newly defined CHA2DS2-
VASc-HS scores can predict the severity of CAD 
in diagnostic coronary angiography, and it was 
reported that CAD severity increased with higher 
scores. In that study, the authors replaced the 
female gender in CHA2DS2-VASc score with male 
gender, and they also incorporated hyperlipidemia 
and smoking as risk factors for the development of 
CAD. The present study aimed to demonstrate the 
value of CHA2DS2-VASc and CHA2DS2-VASc-HS 
scores in predicting failed reperfusion in STEMI 
patients treated with thrombolytic therapy.
Methods
In the present study, data was obtained from 
537 consecutive STEMI patients, who were admit-
ted to our tertiary-care center from January 2008 to 
April 2015 and who received thrombolytic therapy 
based on a clinical decision of the attending car-
diologist.The study was designed retrospectively, 
and complied with the principles of the Declaration 
of Helsinki and the local ethics committee ap-
proved the study protocol. The thrombolytic agent 
administered was a tissue plasminogen activator 
(t-PA; alteplase) or tenectoplase or reteplase. 
The choice of thrombolytic agent was based on 
the decision of the treating physician according to 
recommended doses [11]. Failed thrombolysis was 
defined according to the following criteria; lack of 
symptom relief (worsening ischemia or persistent 
chest pain), presence of hemodynamic or electrical 
instability, ST-segment resolution-related electro-
cardiography leads within 90 min from the initiation 
of the thrombolytic therapy, and in-hospital mor-
tality. Totally 139 patients were defined as failed 
reperfusion according to these criteria. Clinical 
and demographic characteristics including age, 
gender, history of DM, HT, hyperlipidemia, current 
cigarette smoking, family history of premature 
CAD, and chronic heart failure were obtained from 
medical history, physical examination, electrocar-
diographic findings, laboratory data and digital 
and/or non-digital hospital records. low-density 
lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C) and triglyceride 
measurements, and renal function tests were per-
formed by standardized laboratory methods. LDL-C 
concentrations were calculated using the Friede-
wald formula [12]. Hypertension was defined as 
repeated measurements of systolic blood pressure 
> 140 mmHg, diastolic blood pressure > 90 mmHg, 
or chronic treatment with antihypertensive medi-
cations. Type 2 DM was defined as a previous diag-
nosis and/or a fasting blood glucose of > 126 mg/dL 
or the use of anti-diabetic medications. Hyper-
lipidemia was defined by a total cholesterol level 
above 200 mg/dL or use of lipid-lowering medica-
tions. Cigarette smoking was defined as smoking 
≥ 1 cigarettes a day for at least 1 year, without an 
attempt to quit. Family history was defined as the 
presence of heart disease or sudden cardiac death 
in a male first-degree relative aged < 55 years or 
in a female first-degree relative aged < 65 years. 
Chronic heart failure was defined as reduced left 
ventricular ejection fraction (< 40%).
The CHA2DS2-VASc nomenclature represents 
heart failure (C), hypertension (H), age ≥ 75 years 
(A2), diabetes mellitus (D), stroke (S2), vascular dis-
ease (V), age 65 to 74 years (A) and female gender 
(as a sex category [Sc]). The CHA2DS2-VASc score 
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was calculated by assigning 1 point for each of the 
presence of chronic heart failure, HT, DM, age 
65–74 years, female gender and vascular disease 
and by assigning 2 points for history of stroke and 
age > 75 years. The CHA2DS2-VASc-HS score 
comprises hyperlipidemia (H) and smoking (S) 
in addition to the components of CHA2DS2-VASc 
score and male gender instead of female gen-
der (Table 1). The maximum CHA2DS2-VASc 
and CHA2DS2-VASc-HS scores were 9 and 11, 
respectively. 
Statistical analyses
Statistical analyses were conducted using the 
Statistical Package for the Social Sciences (SPSS 
20.0) for Windows (SPSS Inc., Chicago, Illinois, 
USA) and MedCalc 15 statistical software (Os-
tend, Belgium). Continuous data were presented 
as means and standard deviation. The Kolmogo-
rov-Smirnov test was used to evaluate whether 
continuous variables were normally distributed. 
Differences in continuous variables between the 
two groups were determined by Student’s t-test or 
Mann-Whitney U-test. Categorical variables were 
summarized as percentages and were compared 
by the c2 test or Fisher’s exact test. The receiver 
operating characteristics (ROC) curve was also 
used to demonstrate the sensitivity and specificity 
of CHA2DS2-VASc and CHA2DS2-VASc-HS scores 
and their cut-off values for predicting failed reper-
fusion. The area under curve (AUC) comparison 
of these scoring systems was performed using 
the Delong method [13]. A p value < 0.05 was 
considered statistically significant. 
Results
The patients were divided into two groups 
according to the failure (n = 139) or success 
(n = 398) of thrombolysis. The mean age of pa-
tients was 59.9 ± 11.0 years and 82.7% of them 
were male (Table 2). The mean CHA2DS2-VASc 
score was significantly higher in failed reperfu-
sion group than successful reperfusion group 
(2.1 ± 1.4 vs. 1.3 ± 1.2, respectively; p < 0.001). 
Similarly, the mean CHA2DS2-VASc-HS score was 
significantly higher in failed reperfusion group than 
successful reperfusion group (4.1 ± 1.7 vs. 2.6 ± 
± 1.1, respectively; p < 0.001). For the prediction 
of failed reperfusion, the cut-off value of CHA2DS2-
-VASc score was ≥ 2 with a sensitivity of 80.90% 
and a specificity of 41.01% (AUC 0.660; 95% con-
fidence interval [CI] 0.618–0.700; p < 0.001) and 
the cut-off value of CHA2DS2-VASc-HS score was 
≥ 3 with a sensitivity of 76.1% and a specificity of 
67.6% (AUC 0.764; 95% CI 0.725–0.799; p < 0.001) 
in the ROC curve analyses (Fig. 1). The AUC com-
parisons of CHA2DS2-VASc and CHA2DS2-VASc-HS 
scoring systems were performed based on failed 
reperfusion (Fig. 2). Pairwise comparisons of 
ROC curves were also performed and the results 
are demonstrated in Figure 2. Based on these 
results, the CHA2DS2-VASc-HS score was found 
to be better at a statistically significant level than 
CHA2DS2-VASc score to predict failed reperfu-
sion in STEMI patients (p < 0.001). The baseline 
characteristics of both groups are summarized in 
Table 2. History of HT, DM, hyperlipidemia, heart 
failure, smoking, and CAD were significantly more 
Table 1. CHA2DS2-VASc and CHA2DS2-VASc-HS scores.
Nomenclature CHA2DS2-VASc-HS CHA2DS2-VASc
C Congestive heart failure 1 1
H Hypertension 1 1
A2 Age ≥75 years 2 2
D Diabetes mellitus 1 1
S2 History of stroke or TIA 2 2
V Vascular disease 1 1
A Age 65–74 years 1 1
Sc Sex category (male gender) 1 1 (female gender)
H Hyperlipidemia 1 –
S Smoker 1 –
Total maximum 11 9
TIA — transient ischemic attack
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common in failed reperfusion group compared 
to the successful reperfusion group (for all; 
p < 0.05). There was no difference between two 
groups in terms of gender distribution, but the 
mean age of the patients in the failed reperfusion 
group was significantly higher than that of the 
successful reperfusion group (59.6 ± 12.3, 57.3 ± 
± 10.5, respectively; p = 0.032). There were no 
statistically significant differences between two 
groups in levels of laboratory parameters such 
Figure 2. Comparison of receiver-operating characteristics analysis curves according failed reperfusion.
Figure 1. Receiver-operating characteristics analysis curves showing cutoff values for CHA2DS2VASc (A) and CHA2DS2-
-VASc-HS (B) scores for failed thrombolysis in patients with ST-segment elevation myocardial infarction (STEMI).
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as hemoglobin, creatinine, HDL-C and triglyc-
erides. In contrast, total cholesterol and LDL-C 
levels were statistically and significantly higher in 
the failed reperfusion group than in the success-
ful reperfusion group. Similarly, both systolic 
and diastolic blood pressure levels were statisti-
cally and significantly higher in failed reperfusion 
group than in the successful reperfusion group 
(Table 2). 
Discussion
This study demonstrated that the CHA2DS2- 
-VASc and CHA2DS2-VASc-HS scores may be used 
as simple yet powerful tools to aid in prediction of 
failed reperfusion after thrombolytic therapy in 
STEMI patients. In addition, CHA2DS2-VASc-HS 
score was found to be of higher value in predicting 
failed reperfusion compared to the CHA2DS2-VASc 
score.
STEMI is a significantly worldwide cause of 
mortality and morbidity. While PCI is the golden 
standard for the treatment of STEMI patients, 
thrombolytic therapy is recommended in case 
a PCI cannot be performed by an experienced team 
within 90 min after first medical contact [11]. 
Delayed PCI was shown to be associated with 
poor clinical outcomes. While there is no clearly 
defined time for how long PCI can be delayed, it 
was shown that PCI can still be more beneficial 
than thrombolytic therapy in case of delays of up to 
120 min [14, 15]. The most commonly used strat-
egies to evaluate reperfusion after thrombolytic 
therapy include regression of ST segment resolu-
tion, complete recovery from pain or monitoring 
reperfusion arrhythmia. Still, all these parameters 
can be evaluated only after thrombolytic therapy. 
Several studies previously investigated the po-
tential predictors of failed reperfusion. Zairis et al. 
[4] showed that plasma level of CRP on admission 
Table 2. Baseline demographics and clinical characteristics.
Parameters Successful thrombolysis 
(n = 398)
Failed thrombolysis  
(n = 139)
P
Age [year] 57.3 ± 10.5 59.6 ± 12.3 0.032
Male 327 (82.2%) 117 (84.2%) 0.935
Diabetes mellitus 92 (23.1%) 49 (35.3%) 0.005
Hypertension 162 (40.6%) 99 (71.2%) < 0.001
Hyperlipidemia 77 (23.9%) 50 (35.9%) < 0.001
Heart failure 25 (6.3%) 19 (13.7%) 0.006
Stroke – – –
Smoking 234 (62.3%) 114 (82.0%) < 0.001
Coronary artery disease 68 (17.1%) 41 (29.5%) 0.002
Coronary artery bypass grafting 21 (5.3%) 8 (5.8%) 0.830
Family history 99 (24.9%) 31 (22.3%) 0.533
Obesity 79 (24.5%) 32 (23.0%) 0.727
CHA2DS2-VASc 1.3 ± 1.2 2.1 ± 1.4 < 0.001
CHA2DS2-VASc-HS 2.6 ± 1.1 4.1 ± 1.7 < 0.001
Anterior myocardial infarction 125 (31.4%) 42 (30.2%) 0.794
Time from symptom onset to treatment [h] 2.1 ± 0.7 2.1 ± 0.8 0.596
Heart rate [bpm] 75.4 ± 16.8 74.4 ± 17.8 0.554
Systolic blood pressure [mmHg] 128 ± 30 137± 34 0.002
Diastolic blood pressure [mmHg] 76 ± 17 82 ± 19 0.001
Hemoglobin [g/dL] 14.4 ±2.8 14.6 ±2.6 0.792
Creatinine [mg/dL] 0.8 ± 0.1 0.8 ± 0.1 0.856
Total cholesterol [mg/dL] 184 ± 40 201± 51 < 0.001
Low density lipoprotein cholesterol [mg/dL] 108 ± 35 118 ± 45 0.009
High density lipoprotein cholesterol [mg/dL] 41 ± 11 43 ± 17 0.112
Triglycerides [mg/dL] 151 ± 91 146 ± 82 0.131
Data are shown as mean ± standard deviation or number (percentage).
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is a predictor of reperfusion failure after thrombo-
lytic therapy in patients with STEMI. Baysal et al. 
[5] reported that there was a strong and independ-
ent association between increased red cell distribu-
tion width and failed thrombolysis in the setting 
of acute STEMI. Pereg et al. [6] reported in their 
study that a higher mean platelet volume correlated 
with failed thrombolysis in patients presenting with 
STEMI. In addition, Cetin et al. [7] demonstrated 
that an increased platelet distribution width was 
associated with failed reperfusion in STEMI pa-
tients. However, based on available research, there 
is currently no simple and practical scoring system 
that can be used to predict failed reperfusion. The 
CHA2DS2-VASc scores were initially developed for 
thromboembolism risk stratification in patients 
with AF [16]. Recent researches have extended 
the use of the CHA2DS2-VASc score to non-AF 
populations [9, 17–19].  
There are some recently published studies in-
vestigating CHA2DS2-VASc and CHA2DS2-VASc-HS 
scores in patients with acute coronary syndrome 
[17–20]. Bozbay et al. [20] showed that CHA2DS2- 
-VASc score was a predictor of in-hospital and long-
term adverse clinical outcomes in STEMI patients. 
Unal et al. [17] demonstrated that CHA2DS2-VASc 
score was an independent predictor of stent throm-
bosis. Moreover, in their study including patients 
who underwent coronary angiography for STEMI, 
Ipek et al. [19] found that CHA2DS2-VASc score 
was associated with a higher risk of no-reflow 
and in-hospital mortality rates in patients who 
underwent primary PCI due to STEMI. A study by 
Orvin et al. [21] reported that the CHA2DS2-VASc 
score predicted all-cause mortality and death or 
nonfatal myocardial infarction in a significant and 
linear manner. Cetin et al. [9] investigated patients 
who underwent diagnostic angiography and found 
that CHADS2, CHA2DS2-VASc and CHA2DS2-VASc-
-HS scores were significantly correlated with the 
number of diseased coronary vessels and the 
Gensini score. In that study, they developed a new 
scoring system named CHA2DS2-VASc-HS, which 
incorporated hyperlipidemia and smoking, and 
replaced male with female gender in the CHA2DS2-
-VASc score [9]. Similarly, Tasolar et al. [18] found 
a positive correlation between CHA2DS2-VASc-HS 
score and the severity and complexity of CAD in 
patients with non-ST elevation acute coronary 
syndrome [18].
The present results underlined the sig-
nificance of the CHA2DS2-VASc and especially 
CHA2DS2-VASc-HS scores as predictors of failed 
reperfusion after thrombolytic therapy in STEMI 
patients. But, this was the first study performed 
on STEMI patients who were given thrombolytic 
therapy.
In the present study, the significantly elevated 
CHA2DS2-VASc and CHA2DS2-VASc-HS scores 
in patients in the failed reperfusion group can be 
explained by the association between these scores 
and the extent and severity of CAD. Moreover, in 
addition to predicting the severity and seriousness 
of CAD, higher scores also reflect increased throm-
bogenicity and thrombus load [22]. The findings of 
this study are important as they support the fact 
that increasing mean risk scores indicate a higher 
probability of failed reperfusion. The significance 
of both scores in predicting failed reperfusion is 
because their components, including HT, DM, old 
age and heart failure are also separately associated 
with CAD severity and poor outcomes in STEMI 
patients [9, 18, 19]. Moreover, incorporation of 
hyperlipidemia and smoking as risk factors for 
CAD into the newly developed CHA2DS2-VASc 
score further increased the predictive value for 
failed thrombosis. In the CHA2DS2-VASc-HS score, 
female gender in the CHA2DS2-VASc score is 
switched with male gender, which is a risk factor for 
CAD. However, due to the low proportion of female 
patients in this study, the potential impact of gender 
on failed reperfusion could not be demonstrated. 
Additional assessments should be performed in 
larger and distinct populations. 
The CHA2DS2-VASc and CHA2DS2-VASc-HS 
scores represent simple, very useful and easy-
-to-remember bedside score for predicting failed 
reperfusion after thrombolysis in STEMI patients. 
It is believed herein, that these scores, espe-
cially CHA2DS2-VASc-HS, could be used in daily 
practice to estimate failed reperfusion risk for 
patients admitted to non-capable PCI hospitals. In 
addition, these simple scores can help physicians 
to determine transfer strategy for PCI-capable 
hospital such as ambulance or aircraft. If patients 
have a high risk of failed reperfusion, they may 
be referred by aircraft, rather than ambulance for 
faster transfer. 
Limitation of the study
One of the major limitations of this study is 
that it was a single-center study. The absence of 
patients with a history of ischemic or hemorrhagic 
stroke also represents another major limitation. 
Nevertheless, stroke was not excluded from the 
scoring systems in order to guide future stud-
ies and avoid contravening the generic scoring 
systems. 
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Conclusions
Findings of the present study are important 
as they demonstrated that the simple and practical 
CHA2DS2-VASc and CHA2DS2VASc-HS scores can 
be useful in predicting failed reperfusion before 
thrombolytic therapy. In addition, these scores 
can help physicians who work in non-capable PCI 
hospitals to estimate risk of failed reperfusion. 
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